FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 202.2D4	APPLICATION NO. 10/607,035
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	APPLICANT Clarence N. Ahlem, et al	
	FILING DATE June 25, 2003	GROUP 1616

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
BB	3,983,233	9-28-76	Brattsand et al.			
	4,383,992	5-17-83	Lipari			
	4,427,649	1-24-84	Dingle et al.			
	4,710,495	12-1-87	Bodor			
	4,898,694	02-06-90	Schwartz et al.			
	5,001,119	03-19-91	Schwartz et al.			
	5,028,631	07-02-91	Schwartz et al.			
	5,077,284	12-31-91	Loria et al			
	5,206,008	04-27-93	Loria			
	5,223,493	6-29-93	Boltralik			
	5,277,907	06-11-94	Loria			
	5,296,481	03-22-94	Partridge et al			
	5,424,463	06-13-95	Lardy et al.			
	5,461,042	10-24-95	Loria			
	5,506,223	04-09-96	Lardy et al.			
	5,585,371	12-17-96	Lardy			
	5,641,766	06-24-97	Lardy			
	5,686,438	11-11-97	Daynes et al			
	5,714,481	20-03-98	Schwartz et al.			
	5,811,418	09-22-98	Daynes et al			
	5,837,269	11-17-98	Daynes et al.			
	5,859,000	01-12-99	Dowell et al			
	5,912,240	06-15-99	Loria			
	6,187,767 B1	02-13-01	Araneo et al.			5-14-99
	6,197,762 B1	3-6-01	Garvey et al.			9-18-98
	6,667,299 B1	12-23-03	Ahlem et al			3-23-00
BB	6,794,374 B1	09-21-04	Weeks			11-27-00

EXAMINER Badio	DATE CONSIDERED 10/12/05

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 202.2D4	APPLICATION NO. 10/607,035
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT Clarence N. Ahlem, et al	
(USE SEVERAL SHEETS IF NECESSARY)	FILING DATE June 25, 2003	GROUP 1616

U.S. PATENT APPLICATION PUBLICATIONS

EXAMINER INITIAL		DOCUMENT PUBLICATION NUMBER	NAME AND PORTIONS OF DOCUMENT	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
BB		US 2005/0075321 A1	Ahlem et al., first page and pages 102-107 (claims)			
		US 2004/0138187 A1	Ahlem et al., entire document			
		US 2004/0083231 A1	Ahlem et al., entire document			
		US 2004/0043973 A1	Ahlem et al., first page and pages 99-101 (claims)			
BB		US 2003/0060425 A1	Ahlem et al., entire document			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
BB		EP 0 429 187 B1	05-01-94	Europe				
		EP 0 289 327 A1	11-02-88	Europe				
		EP 0 133 995 A2	08-08-84	Europe				
BB		DE 38 12 595 C2	10-27-88	Germany			X	

Radio 10/12/05

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 202.2D4	APPLICATION NO. 10/607,035
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT Clarence N. Ahlem, et al	
(USE SEVERAL SHEETS IF NECESSARY)	FILING DATE June 25, 2003	GROUP 1616

EXAMINER INITIAL		OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, ETC.)
BB		Araghi-Niknam et al., Cytokine Dysregulation and Increased Oxidation IS Prevented by Dehydroepiandrosterone in Mice Infeced with Murine Leukemia Retrovirus, *Proc. Soc. Exp. Biol. Med.* 216(3):386-391 1997
		Araghi-Niknam et al., Modulation of immune dysfunction during murine leukaemia retrovirus infection of old mice by dehyroepiandrosterone sulphate (DHEAS), *Immunology* 90:344-349 1997
		Bebo et al., Androgens alter the cytokine profile and reduce encephalitogenicity of myelin-reactive T cells, *J. Immunol.* 162:35-40 1999
		Henderson et al., Dehydroepiandrosterone and 16.alpha.-bromoepiandrosterone: Inhibitors of Epstein-Barr virus induced transformation of human lymphocytes, *Carcinogenesis*, 2(7):683-686 1981
		Hernandez-Pando et al., The effects of androstenediol and dehydroepiandrosterone on the course and cytokine profile of tuberculosis in BALB/c mice, *Immunology* 95(2):234-241 1998
		Inserra et al., Modulation of cytokine production by dehydroepiandrosterone (DHEA) plus melatonin (MLT) supplementation of old mice, *Proc. Soc. Exp. Biol. Med.* 218:76-82 1998
		Kang et al., Dehydroepiandrosterone and β-endorphin enhance IL-12 gene expression, *Chem. Abstracts* 126(9):99 abstract No. 113406a 1997
		Kang et al., Dehydroepiandrosterone and β-endorphin enhance IL-12 gene expression, *Taehan Misaengmulhak Hoechi (J. Korean Soc. Microbiology)* 31(4):399-404 1996 (translation from Korean)
		Manz et al., Methyl 17ß-Carboxyester Derivatives of Natural and Synthetic Glucocorticoids: Correlation Between Receptor Binding and Inhibition of in vitro Phytohaemagglutinin-Induced Lymphocyte Blastogenesis, *J. Clin. Chem. Clin. Biochem.* 21(2):69-75 1983
		Sigg et al., Methyl 3α-acetoxyetien-(8:9 oder 8:14)-ate, Preliminary Communication, *Helvetica Chimica Acta*, 39(6):1507-1525 1956 (translation from German)
		Weisz et al., Selective reations of some steroids with diethyl dicarbonate, *Archiv Pharmazie* 319:952-953 1986
		Xia, et al., Anti-AIDS agents. Part 36: 17-Carboxylated steroids as potential anti-HIV agents, *BIOORG Med. Chem* 7(9):1907-1911 1999
		Yang et al., Inhibition of HIV-1 latency reactivation by dehydroepiandrosterone (DHEA) and an analog of DHEA, *Aids Research and Human Retroviruses* 9(8):747-754 1993
BB		Zhang et al., Prevention of immune dysfunction and vitamin E loss by dehydroepiandrosterone and melatonin supplementation during murine retroivirus infection, *Immunology* 96:291-297 1999

Bodie 10/12/05